High Blood Pressure Exercise Program

Natural High Blood Pressure Treatment Ebook

Get Instant Access

1. Alquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586-600.

2. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. Br J Ophthalmol. 1967;51:222-226.

3. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27: 135-142.

4. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol. 1983;28(suppl):286-292.

5. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure: in the normal eye. Arch Ophthalmol. 1978;96:2045-2048.

6. Gaul GR, Will NJ, Brubaker RF. Comparison of a noncardioselective beta-adreno-ceptor blocker and a cardioselective blocker in reducing aqueous flow in humans. Arch Ophthalmol. 1989;107:1308-1311.

7. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369-1372.

8. Yablonski ME, Novack GD, Burke PJ, et al. The effect of levobunolol on aqueous humor dynamics. Exp Eye Res. 1987;44:49-54.

9. Schmitt C, Lotti VJ, DeDouarec JC. Beta-adrenergic blockers: lack of relationship between antagonism of isoproterenol and lowering of intraocular pressure in rabbits. In: Sears ML, ed. New Directions in Ophthalmic Research. New Haven, CT: Yale University Press; 1981:147-162.

10. Caprioli J, Sears M, Bausher L, et al. Forskolin lowers intraocular pressure by reducing aqueous inflow. Invest Ophthalmol Vis Sci. 1984;25:268-277.

11. Keates EU, Stone R. The effect of d-timolol on intraocular pressure in patients with ocular hypertension. Am J Ophthalmol. 1984;98:73-78.

12. Polansky JR, Cherksey BD, Alvarado JA. Update on -adrenergic drug therapy. In: Drance SM, Van Buskirk EM, Neufeld AH, eds. Pharmacology of Glaucoma. Baltimore, MD: Williams & Wilkins; 1992:301-321.

Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma [editorial]. Arch Ophthalmol. 1997;115:1579-1580.

Kitazawa Y, Tsuchisaka H. Effects of timolol on corneal sensitivity and tear production. Int Ophthalmol. 1980;3:25-29.

Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol. 1979;88:739-743.

Wilson RP, Spaeth GL, Poryzees E. The place of timolol in the practice of ophthalmology. Ophthalmology. 1980;87:451-454.

Berry DP Jr, Van Buskirk EM, Shields MB. Betaxolol and timolol: a comparison of efficacy and side effects. Arch Ophthalmol. 1984;102:42-45.

Allen RC, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol. 1986;101:535-541.

Mills KB, Wright G. A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. Br J Ophthalmol. 1986;70:39-42.

Weinreb RN, Caldwell DR, Goode SM, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol. 1990;110:189-192.

Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol maleate on tear flow in human eyes. Graefes Arch Klin Exp Ophthalmol. 1980;213:19-22. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082-1088. Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid: a spectrum of diseases. Arch Ophthalmol. 1987;105:1660-1663.

Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol. 1987;31: 307-327.

Kinshuck D. Glauline (metipranolol) induced uveitis and increase in intraocular pressure. Br J Ophthalmol. 1991;75:575.

Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519-523.

Akingbehin T, Villada JR, Walley T. Metipranolol-induced adverse reactions, I: the rechallenge study. Eye. 1992;6:277-279.

Schultz JS, Hoenig JA, Charles H. Possible bilateral anterior uveitis secondary to metipranolol (OptiPranolol) therapy. Arch Ophthalmol. 1993;111:1606-1607. Melles RB, Wong IG. Metipranolol-associated granulomatous iritis. Am J Oph-thalmol. 1994;118(6):712-715.

Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207-218.

Bobik A, Jennings GL, Asley P, et al. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration. Eur J Clin Pharmacol. 1979;16:243-249.

Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Arch Clin Exp Ophthalmol. 1995;233:131-134. Affrime MB, Lowenthal DT, Tobert JA, et al. Dynamics and kinetics of ophthalmic timolol. Clin Pharmacol Ther. 1980;27:471-477.

Alvan G, Calissendorff B, Seideman P, et al. Absorption of ocular timolol. Clin Pharmacokmet. 1980;5:95-100.

Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551-553. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87:447-450.

McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol. 1979;88:736-738. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol. 1987;103:592. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol. 1987;7:264-267. Lynch MG, Whitson JT, Brown RH, et al. Topical beta-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol. Arch Ophthalmol. 1988;106:908-911.

Cohen JB. A comparative study of the central nervous system effects of betaxolol versus timolol [letter]. Arch Ophthalmol. 1989;107:633-634. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. The Pharmacologic Basis of Therapeutics. New York: McGraw-Hill; 1996:199-248. Hjalmarson A. Prevention of sudden cardiac death with beta blockers. Clin Cardiol. 1999;22(suppl 5):V11-V15.

Yan AT, Yan RT, Liu PP. Narrative review. pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med. 2005;142(2):132-145. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol. 1999;84:94R-102R.

Domanski MJ, Krause-Steinrauf H, Massie BM, et al; BEST Investigators. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure. BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5):354-363. Burggraf GW, Munt PW. Topical timolol therapy and cardiopulmonary function. Can J Ophthalmol. 1980;15:159-160.

Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986;104:197-199.

Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986; 102:606-611.

Doyle WJ, Weber PJ, Meeks RH. Effects of topical timolol maleate on exercise performance. Arch Ophthalmol. 1984;102:1517-1518.

Atkins JM, Pugh BR Jr, Timewill RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol. 1985;99:173-175.

Zabel RW, MacDonald IM. Sinus arrest associated with betaxolol ophthalmic drops. Am J Ophthalmol. 1987;104:431.

Rosenlund EF. The intraocular pressure lowering effect of timolol in gel-forming solution [published correction appears in Acta Ophthalmol Scand. 1996;74(4):416]. Acta Ophthalmol Scand. 1996r;74(2):160-162.

Kitazawa Y. Multicenter double-blind comparison of carteolol and timolol in primary open-angle glaucoma and ocular hypertension. Adv Ther. 1993;10:95-131. Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1997;123:465-477.

Jones FL Jr, Ekberg NL. Exacerbation of asthma by timolol [letter]. N Engl J Med. 1979;301:270.

Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA. 1981;245:1460-1461.

Prince DS, Carliner NH. Respiratory arrest following first dose of timolol ophthalmic solution. Chest. 1983;84:640-641.

Avorn J, Glynn RJ, Gurwitz JH, et al. Adverse pulmonary effects of topical beta blockers used in the treatment of glaucoma. J Glaucoma. 1993;2:158-165. Charan NB, Lakshminarayan S. Pulmonary effects of topical timolol. Arch Intern Med. 1980;140:843-844.

Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984;97:86-92.

Diggory P, Heyworth P, Chau G, et al. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye. 1993;7:661-663.

Van Buskirk EM, Weinreb RN, Berry DP, et al. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol. 1986;101:531-534.

Ofner S, Smith TJ. Betaxolol in chronic obstructive pulmonary disease. J Ocul Pharmacol. 1987;3:171-176.

Weinreb RN, Van Buskirk EM, Cherniack R, Drake MM. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol. 1988;106: 162-167.

Harris LS, Greinstein SH, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol. 1986;102:274-275.

Berger WE. Betaxolol in patients with glaucoma and asthma [letter]. Am J Ophthalmol. 1987;103:600-601.

Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease. a meta-analysis. Ann Intern Med. 2002;137(9): 715-725.

Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease. a meta-analysis. Respir Med. 2003;97(10):1094-1101.

Coleman AL, Diehl DL, Jampel HD, et al. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol. 1990;108:1260-1263. West J, Longstaff S. Topical timolol and serum lipoproteins. Br J Ophthalmol. 1990;74:663-664.

Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116: 600-611.

Realini T, Barber L, Burton D. Frequency of asymmetric intraocular pressure fluctuations among patients with and without glaucoma. Ophthalmology. 2002;109: 1367-1371.

Realini T, Fechtner RD, Atreides, SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology. 2004;111:421-426. Liu JHK, Sit AJ, Weinreb RN. Variation of 24-hour intraocular pressure in healthy individuals. Ophthalmology. 2005;112:1670-1675.

Goldberg I, Ashburn FS Jr, Palmberg PF, et al. Timolol and epinephrine: a clinical study of ocular interactions. Arch Ophthalmol. 1980;98:484-486.

Korey MS, Hodapp E, Kass M, et al. Timolol and epinephrine: long-term evaluation of concurrent administration. Arch Ophthalmol. 1982;100:742-745. Cyrlin MN, Thomas JV, Epstein DL. Additive effect of epinephrine to timolol therapy in primary open angle glaucoma. Arch Ophthalmol. 1982;100:414-418. Weinreb RN, Ritch R, Kushner FH. Effect of adding betaxolol to dipivefrin therapy. Am J Ophthalmol. 1986;101:196-198.

Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Arch Ophthalmol. 1986;104:1178-1184.

Airaksinen PJ, Valkonen R, Stenborg T, et al. A double-masked study of timolol and pilocarpine combined. Am J Ophthalmol. 1987;104:587-590. Kass MA, Korey M, Gordon M, Becker B. Timolol and acetazolamide: a study of concurrent administration. Arch Ophthalmol. 1982;100:941-942. Smith JP, Weeks RH, Newland EF, Ward RL. Betaxolol and acetazolamide: combined ocular hypotensive effect. Arch Ophthalmol. 1984;102:1794-1795. Adamsons I, Clineschmidt D, Polis A, et al. The efficacy and safety of dorzol-amide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group. J Glaucoma. 1998;7:253-260.

Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952-1959. Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268-273.

Alm A,Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concom-itantly with timolol. Br J Ophthalmol. 1995;79:12-16.

Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.

Orengo-Nania S,Landry T, Von Tress M, et al. Evaluation of travoprost as adjunc-tive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol. 2001;132:860-868.

Blondeau P, Cote M, Tetrault L. Effect of timolol eye drops in subjects receiving systemic propranolol therapy. Can J Ophthalmol. 1983;18:18-21. Batchelor ED, O'Day DM, Shand DG, Wood AJ. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979;86:60-65.

Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. BMJ. 1987;294:155-156.

Dinai Y, Sharir M, Naveh N, Halkin H. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med. 1985;103:890-891.

Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA.


Lama PJ. Systemic adverse effects of beta-adrenergic blockers. an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749-760.

Kohn RJ. Beta-blockers an important cause of depression. a medical myth without evidence. Med Health R I. 2001;84:92-95.

Paauw DS. Did we learn evidenced-based medicine in medical school? Some common medical mythology. J Am Board Fam Prac. 1999;12:143-149. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and cap-topril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998;317:713-720.

Shorr RS, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997; 278:40-43.

Boger WP III, Steinert RF, Puliafito CA, Pavan-Langston D. Clinical trial comparing timolol ophthalmic solution to pilocarpine in open-angle glaucoma. Am J Oph-thalmol. 1978;86:8-18.

Sonntag JR, Brindley GO, Shields MB, et al. Timolol and epinephrine: comparison of efficacy and side effects. Arch Ophthalmol. 1979;97:273-277. Katz IM, Hubbard WA, Getson AJ, Gould AL. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol. 1976;15: 489-492.

Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol. 1977;95:605-607.

Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979;97:656-658.

Demailly P, Lehner MA, Etienne R, et al. Results of a double-blind medium-term study comparing effects of timolol maleate and epinephrine in 120 patients with chronic open-angle glaucoma. J Fr Ophthalmol. 1978;1:727-732. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol. 1979;23:395-398.

Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601-604.

Shin DH. Bilateral effects of monocular timolol treatment. Am J Ophthalmol.


Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315-1319. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389-395.

Letchinger SL, Frohlichstein D, Glieser DK, et al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology. 1993;100: 1259-1262.

Wandel T, Charap AD, Lewis RA, et al. Glaucoma treatment with once-daily levo-bunolol. Am J Ophthalmol. 1986;101:298-304.

Soll DB. Evaluation of timolol in chronic open-angle glaucoma: once a day vs twice a day. Arch Ophthalmol. 1980;98:2178-2181.

Shedden AH, Laurence J, Barrish A, Olah TV. Plasma timolol concentrations of timolol maleate. timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol. 2001;103(1):73-79. Mundorf TK, Cate EA, Sine CS, et al. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther. 1998;14:129-135.

Mundorf TK, Ogawa T, Naka H, Novack GD, Crockett RS; US Istalol Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther. 2004;26(4): 541-551.

Araie M, Takase M. Effects of S-596 and carteolol, new beta-adrenergic blockers, and flurbiprofen on the human eye: a fluorophotometric study. Graefes Arch Klin Exp Ophthalmol. 1985;222:259-262.

Negishi C, Ueda S, Kanai A, et al. Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Acta Soc Ophthalmol Jpn. 1981;25:464-476. Stewart WC, Cohen JS, Netland PA, et al. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol. 1997;124:498-505.

Scoville B, Mueller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol. 1988;105:150-154. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers. importance of ancillary properties. Prog Cardiovasc Dis. 1997;39(5):445-456. Duzman E, Ober M, Scharrer A, Leopold IH. A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure. Am J Ophthalmol. 1982;94:318-327.

Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology. 1989;96:8-11.

Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol (0.5%) therapy: a crossover study. Ophthalmology. 1992;99:424-429. Berson FG, Cohen HB, Foerster RJ, et al. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol. 1985;103: 379-382.

Cinotti A, Cinotti D, Grant W, et al. Levobunolol vs timolol for open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1985;99:11-17.

Levobunolol Study Group. Levobunolol: a four-year study of efficacy and safety in glaucoma treatment. Ophthalmology. 1989;96:642-645.

Krieglstein GK, Novack GD, Voepel E, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. Br J Ophthalmol. 1987;71: 250-253.

Dausch D, Brewitt H, Edelhoff R. Metipranolol eye drops: clinical suitability in the treatment of chronic open angle glaucoma. In: Merte H-J, ed. Metipranolol: Pharmacology of Beta-Blocking Agents and Use of Metipranolol in Ophthalmology. Contributions to the First Metipranolol Symposium, Berlin, 1983. New York: SpringerVerlag; 1984:132-147.

Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, beta-1 adrenergic antagonist. Am J Ophthalmol. 1985;100:777-782.

Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol. 1984;102:539-540.

Berrospi AR, Leibowitz HM. Betaxolol: a new beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1982;100:943-946. Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Arch Ophthalmol. 1983;101:898-900.

Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol: a six-month doubleblind comparison. Arch Ophthalmol. 1986;104:46-48.

135. Feghali JG, Kaufman PL, Radius RL, Mandell AI. A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension. Acta Ophthalmol. 1988;66: 180-186.

136. Long DA, Johns GE, Mullen RS, et al. Levobunolol and betaxolol: a double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology. 1988;95:735-741.

137. Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol. 1991;112:678-681.

138. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv Ophthalmol. 1994;38(suppl): S156-S160.

139. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol. 1994;38(suppl):149-155.

140. Hoste AM, Sys SU. Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J Cardiovasc Pharmacol. 1998;32:390-396.

141. Yu DY, Su EN, Cringle SJ, et al. Effect of betaxolol, timolol and nimodipine on human and pig retinal arterioles. Exp Eye Res. 1998;67:73-81.

142. Osborne NN, Cazevieille C, Carvalho AL, et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 1997;751:113-123.

143. Wood JP, DeSantis L, Chao HM, Osborne NN. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp Eye Res. 2001;72(1):79-86.

144. Metoki T, Ohguro H, Ohguro I, Mamiya K, Ito T, Nakazawa M. Study of effects of antiglaucoma eye drops on N-methyl-D-aspartate-induced retinal damage. Jpn J Ophthalmol. 2005;49(6):453-461.

145. Cheon EW, Park CH, Kim YS, et al. Protective effects of betaxolol in eyes with kainic acid-induced neuronal death. Brain Res. 2006;1069(1):75-85. Epub 2006 Jan 4.

Was this article helpful?

0 0
Dealing With Bronchitis

Dealing With Bronchitis

If you're wanting to know more about dealing with bronchitis... Then this may be the most important letter you'll ever read! You are About To Read The Most Important Information That Is Available To You Today, You Will Achieve A Better Understanding About Bronchitis! It doesn't matter if you've never had bronchitis before or never known anyone who has, This guide will tell you everything you need to know, without spending too much brainpower!

Get My Free Ebook

Post a comment